{"id":3934,"date":"2026-10-25T09:00:00","date_gmt":"2026-10-25T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3934"},"modified":"2026-10-27T20:53:11","modified_gmt":"2026-10-28T00:53:11","slug":"jnj-6143-tests-induced-proximity-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3934","title":{"rendered":"JNJ 6143 Tests Induced Proximity in Prostate Cancer"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson & Johnson (Halda-derived)<\/p>\n

Event Type<\/strong><\/p>\n

Phase I clinical data, ESMO (source-gap recovery)<\/p>\n

Modality<\/strong><\/p>\n

RIPTAC induced-proximity small molecule<\/p>\n

Asset<\/strong><\/p>\n

JNJ-6143 (HLD-0915)<\/p>\n

Target<\/strong><\/p>\n

Androgen receptor and BRD4<\/p>\n

Disease Area<\/strong><\/p>\n

Metastatic castration-resistant prostate cancer<\/p>\n

Summary<\/h4>\n

Source-gap recovery: Johnson & Johnson\u2019s 25 October ESMO Phase I disclosure, absent from the reviewed Insilens history, provides first human activity for its Halda-derived RIPTAC platform. The single-arm, selected-dose results are hypothesis-generating rather than evidence of superiority.<\/p>\n

At 50 mg once daily, 12 of 16 patients with measurable metastatic castration-resistant prostate cancer reportedly had a confirmed RECIST response. Among 38 patients at that dose, 77% had a confirmed PSA50 decline and 48% PSA90. Median prior lines were four. Seventy-one percent remained on treatment at 5.6 months median follow-up. Reported treatment-related events included hypercholesterolemia (18%), nausea (16%) and hypertriglyceridemia (16%); one patient discontinued for adverse events. A Phase II study is planned or ongoing. The original release was 25 October, not 27 October.<\/p>\n

Deep Analysis<\/h4>\n

RIPTAC is induced proximity, but not conventional proteolysis: the molecule brings androgen receptor and essential BRD4 together to disrupt cell survival. The dose-level objective response is notable in a heavily treated setting, but the denominator of 16 measurable patients is small and selected from a larger treated cohort. PSA declines alone do not prove survival benefit. The release lacks mature response duration, randomized comparator, full molecular strata, pharmacodynamic target engagement, off-target transcriptional effects and longer safety. AR expression may provide selectivity, but AR-low or lineage-plastic disease could escape. J&J bought Halda in 2025; this first clinical readout tests whether the acquired chemistry translates beyond preclinical models.<\/p>\n

Company and Product Background<\/h4>\n

JNJ-6143, formerly HLD-0915, is an oral small molecule designed to bind androgen receptor and BRD4 simultaneously. It is studied after standard prostate-cancer therapies in metastatic castration-resistant disease.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> essential-protein sequestration creates a new AR-dependent vulnerability; concordant imaging and PSA responses support it.<\/li>\n
  • Interpretation B:<\/strong> selected-dose, small-denominator effects and androgen biology may account for much of the apparent signal; short follow-up and no control support caution.<\/li>\n
  • Upgrade<\/strong> with randomized PFS, durable RECIST responses, mechanism biomarkers and resistance mapping. Downgrade<\/strong> with toxicity or AR-independent escape. Falsification:<\/strong> controlled efficacy fails despite confirmed target engagement.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is a meaningful first human platform signal, not validation that RIPTAC displaces established AR, taxane or radioligand treatments.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: positive early activity; durability uncertain. Confidence in Facts: high. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Source-gap recovery: Johnson & Johnson\u2019s 25 October ESMO Phase I disclosure, absent from the reviewed Insilens history, provides first human activity for its Halda-derived RIPTAC platform. The single-arm, selected-dose results are hypothesis-generating rather than…<\/p>\n","protected":false},"author":1,"featured_media":3942,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1251,1249,79,262,1250],"class_list":["post-3934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-induced-proximity","tag-jnj-6143","tag-johnson-johnson","tag-prostate-cancer","tag-riptac"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3934"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3934\/revisions"}],"predecessor-version":[{"id":3954,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3934\/revisions\/3954"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3942"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}